Author

Paul W.G. Wijnhoven

AstraZeneca (United Kingdom)ORCID 0000-0002-5489-3006Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Alaide MorcavalloiD· 1 shared Anna Dominika StaniszewskaiD· 1 shared Anna Louise Beckett· 1 shared Elsa IrvingiD· 1 shared Jekaterina Vohhodina-TretjakovaiD· 1 shared Jennifer I. MossiD· 1 shared Josep V. FormentiD· 1 shared Michael P. Jacques· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alaide MorcavalloORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologyCancersPeer-reviewedJan 20, 2026

An inducible BRCA1 expression system with in vivo applicability uncovers activity of the combination of ATR and PARP inhibitors to overcome therapy resistance

Elsa Irving, Alaide Morcavallo, Jekaterina Vohhodina-Tretjakova…·Josep V. Forment

This paper develops an inducible BRCA1 expression system to study hypomorphic variants and finds that combining ATR and PARP inhibitors overcomes resistance caused by BRCA1 {Delta}exon11 hypomorphs.

1 citation

humanbulk RNA-seq

𝕏 PostBluesky